Genentech Reports P-III Study (OCARINA II) Results of Ocrevus for the Treatment of Multiple Sclerosis
Shots:
- The P-III study evaluating Ocrevus (twice-yearly, 10min. SC inj.) vs Ocrevus (IV) in 236 patients with RMS or primary progressive MS (PPMS)
- The results showed that Ocrevus (SC) was non-inferior to IV infusion based on Ocrevus levels in the blood over 12wks. & was comparable to IV infusion in providing rapid & sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24wks. (97% vs 98% had B cell levels of 5 cells/µL or less when first measured at 14 days)
- Peak Ocrevus blood concentrations were similar for SC inj. & IV infusion. The safety profile was consistent with Ocrevus IV infusion, results will be presented at the 9th Joint ECTRIMS-ACTRIMS Meeting & will be submitted to health authorities in the coming months globally
Ref: Businesswire | Image: Genentech
Related News:- Orionis Biosciences Entered into a Multi-Year Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
